NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Jayachandran, Gitanjali ^a   Ueda, Kentaro ^a,c   Wang, Bingbing ^a   Roth, Jack A ^a,b   Ji, Lin ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CASPASE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DNA FRAGMENT; GENE THERAPY AGENT; HISTONE H2AX; NIBRIN; NITROGEN PERMEASE REGULATOR 2 PROTEIN; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; NBN PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN; TUSC4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLEURA METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA; MUS;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LUNG NEOPLASMS; MICE; NUCLEAR PROTEINS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 77957814634     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011994     Document Type: Article

References (50)

1. Lerman MI, Minna JD (2000) The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 60: 6116-6133.
2. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, et al. (2002) Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62: 2715-2720.
3. Zabarovsky ER, Lerman MI, Minna JD (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915-6935.
4. Schenk PW, Brok M, Boersma AW, Brandsma JA, Den Dulk H, et al. (2003) Anticancer drug resistance induced by disruption of the Saccharomycescerevisiae NPR2 gene: a novel component involved in cisplatin and doxorubicin-provoked cell kill. Mol Pharmacol 64: 259-268.
5. Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, et al. (2006) The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 66: 9682-9690.
6. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344.
7. Lin WC, Lin FT, Nevins JR (2001) Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: 1833-1844.
8. Zhao H, Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21: 4129-4139.
9. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ (2001) ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276: 42462-42467.
10. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, et al. (2003) Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5: 675-679.
11. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, et al. (2003) H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114: 371-383.
12. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, et al. (2002) DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 4: 993-997.
13. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ (2003) MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421: 961-966.
14. Gatei M, Sloper K, Sorensen C, Syljuäsen R, Falck J, et al. (2003) Ataxiatelangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278: 14806-14811.
15. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, et al. (2002) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 97: 10389-10394.
16. Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY, et al. (2002) SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev 16: 571-582.
17. Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439.
18. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, et al. (2000) High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60: 1949-1960.
19. Fondon JW, 3rd, Mele GM, Brezinschek RI, Cummings D, Pande A, et al. (1998) Computerized polymorphic marker identification: experimental validation and a predicted human polymorphism catalog. Proc Natl Acad Sci U S A 95: 7514-7519.
20. Ji L, Fang B, Yen N, Fong K, Minna JD, et al. (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59: 3333-3339.
21. Lassus P, Opitz-Araya X, Lazebnik Y (2002) Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297: 1352-1354.
22. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S (2002) Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 277: 29803-29809.
23. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663.
24. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542.
25. Henkels KM, Turchi JJ (1997) Induction of apoptosis in cisplatin-sensitive and - resistant human ovarian cancer cell lines. Cancer Res 57: 4488-4492.
26. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, et al. (2002) Genomic instability in mice lacking histone H2AX. Science 296: 922-927.
27. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM (2000) Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 275: 9390-9395.
28. Talasz H, Helliger W, Sarg B, Debbage PL, Puschendorf B, et al. (2002) Hyperphosphorylation of histone H2AX and dephosphorylation of histone H1 subtypes in the course of apoptosis. Cell Death Differ 9: 27-39.
29. Donzelli M, Draetta GF (2003) Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 4: 671-677.
30. Ahn JY, Li X, Davis HL, Canman CE (2002) Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem 277: 19389-19395.
31. Xu X, Tsvetkov LM, Stern DF (2002) Chk2 activation and phosphorylationdependent oligomerization. Mol Cell Biol 22: 4419-4432.
32. Brown EJ, Baltimore D (2003) Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 17: 615-628.
33. Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897.
34. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, et al. (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18: 4047-4054.
35. Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, et al. (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288: 1425-1429.
36. Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, et al. (2002) Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. Embo J 21: 5911-5920.
37. O'Neill T, Giarratani L, Chen P, Iyer L, Lee CH, et al. (2002) Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. J Biol Chem 277: 16102-16115.
38. Motoyama N, Naka K (2004) DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 14: 11-16.
39. Brown AL, Lee CH, Schwarz JK, Mitiku N, Piwnica-Worms H, et al. (1999) A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc Natl Acad Sci U S A 96: 3745-3750.
40. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410: 842-847.
41. Bartek J, Lukas J (2001) Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 13: 738-747.
42. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J (2002) The DNA damagedependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 30: 290-294.
43. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, et al. (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505.
44. Sanchez Y, Wong C, Thoma RS, et al. (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277: 1497-1501.
45. Sorenson CM, Barry MA, Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755.
46. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362.
47. Evans DL, Tilby M, Dive C (1994) Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 54: 1596-1603.
48. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 8: 2963-2969.
49. Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280.
50. Evans DL, Tilby M, Dive C (1994) Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 54: 1596-1603.